CLINICAL TRIALS PROFILE FOR REBETOL

All Clinical Trials for REBETOL

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00018031 ↗	Peginterferon Alpha-2b And Ribavirin to Treat Hepatitis C in HIV-Infected Patients	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2	2001-06-01	This study will evaluate the safety and effectiveness of combination therapy with peginterferon alfa-2b and ribavirin for treating hepatitis C virus (HCV) infection in HIV-infected patients. In studies of patients with hepatitis C alone, interferon alfa-2b plus ribavirin treatment eradicated the HCV in almost half the patients. Peginterferon alfa-2b is a compound that results from attaching a polyethylene glycol molecule to interferon alfa-2b. This compound stays in the blood longer than unmodified interferon alfa-2b, causing a higher blood concentration and thus maintaining activity against the hepatitis C virus. HIV-infected patients 21 years of age and older with chronic hepatitis C infection and a viral load greater than 2000 copies/mL may be eligible for this 2 1/2-year study. Candidates will be screened with blood and urine tests and possibly a liver biopsy, if a recent one is not available. The liver biopsy is done to determine the severity of liver disease. For this test, patients are admitted to the NIH Clinical Center for 1 to 2 days. A sedative is injected into an arm vein, the skin in the area over the biopsy site is numbed with a local anesthetic, and a needle is inserted rapidly into and out of the liver to obtain a small tissue sample. The patient remains in the hospital overnight for monitoring. A chest X-ray, electrocardiogram (EKG) and liver ultrasound are also done. Within 4 weeks of the screening tests, candidates who appear eligible for the study will have a physical examination, medical history and repeat blood tests. Women who can become pregnant will have serial pregnancy tests throughout the study. Patients who meet the study criteria and decide to participate will begin treatment with weekly injections under the skin of peginterferon alfa-2b and take ribavirin pills twice a day by mouth. In addition, patients will continue to take all other medications prescribed by their doctor. Clinic visits will be scheduled as follows: - Days 1, 3, 5, 7, 10 and 21 - Blood will be drawn for safety tests and to measure blood levels of HIV and HCV. - Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 52, 56 and 64 - Blood and urine tests will be done to determine the side effects of treatment and its effect on the HCV infection. - Week 48 or end of treatment - Treatment will stop after 48 weeks. At this time, or earlier for those who do not complete the 48 weeks, patients will return to the clinic for a routine test.
NCT00039871 ↗	PEG-Intron Plus Rebetol Treatment of Chronic Hepatitis C Subjects Who Failed Response to Alpha-Interferon Plus Ribavirin (Study P02370)	Completed	Merck Sharp & Dohme Corp.	Phase 3	2002-05-01	The objective of this study is to determine the effectiveness of PEG-Intron 1.5 ug/kg/wk plus REBETOL (ribavirin) 800-1400 mg/day in adults with chronic hepatitis C with moderate to severe liver fibrosis or cirrhosis who failed to respond to previous treatment with an alpha interferon in combination with ribavirin. Patients who do not respond to PEG-Intron plus REBETOL (ribavirin) will be enrolled in a long-term maintenance study to evaluate the effectiveness of PEG-Intron monotherapy versus no treatment for the prevention of disease progression (Protocols P02569 and P02570).
NCT00081770 ↗	Peginterferon Dose Evaluations for Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03471)	Completed	Merck Sharp & Dohme Corp.	Phase 3	2004-03-01	The objective is to compare the safety and efficacy of the following three treatment regimens in previously untreated adult subjects with chronic hepatitis C infected with Genotype 1: (1) PegIntron 1.5 µg/kg/wk in combination with weight based REBETOL (800-1400 mg/day); (2) PegIntron 1µg/kg/wk in combination with weight based REBETOL (800-1400 mg/day); and (3) PEGASYS 180 µg/wk plus COPEGUS 1000-1200 mg/day.
NCT00087607 ↗	Peak Study - A Study of Pegasys (Peginterferon Alfa-2a (40KD)) in Combination With Copegus (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC).	Completed	Hoffmann-La Roche	Phase 4	2004-01-01	This study will examine the viral kinetics and pharmacokinetics of Pegasys plus ribavirin and PEG-Intron plus ribavirin in interferon-naive patients with CHC. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.
NCT00104052 ↗	Study of PEG-Intron Plus REBETOL in Pediatric Subjects With Chronic Hepatitis C (Study P02538 Part 1)	Completed	Merck Sharp & Dohme Corp.	Phase 3	2005-02-01	The primary objective is to assess the safety, efficacy and tolerability of the combination of PEG-Intron plus REBETOL in pediatric subjects with chronic hepatitis C. The secondary objective is to measure the multiple-dose pharmacokinetics of PEG-Intron and REBETOL in pediatric subjects with chronic hepatitis C.

Clinical Trial Conditions for REBETOL

Condition Name

Condition Name for REBETOL
Intervention	Trials
Hepatitis C, Chronic	47
Hepatitis C	29
Chronic Hepatitis C	19
Hepacivirus	6

Condition MeSH

Condition MeSH for REBETOL
Intervention	Trials
Hepatitis C	89
Hepatitis	84
Hepatitis A	74
Hepatitis C, Chronic	74

Clinical Trial Locations for REBETOL

Trials by Country

Trials by Country for REBETOL
Location	Trials
United States	59
Japan	8
Egypt	4
Germany	4
Netherlands	4

Trials by US State

Trials by US State for REBETOL
Location	Trials
Texas	6
California	6
Virginia	5
New York	4
Florida	3

Clinical Trial Progress for REBETOL

Clinical Trial Phase

Clinical Trial Phase for REBETOL
Clinical Trial Phase	Trials
Phase 4	18
Phase 3	19
Phase 2/Phase 3	2

Clinical Trial Status

Clinical Trial Status for REBETOL
Clinical Trial Phase	Trials
Completed	69
Terminated	15
Withdrawn	6

Clinical Trial Sponsors for REBETOL

Sponsor Name

Sponsor Name for REBETOL
Sponsor	Trials
Merck Sharp & Dohme Corp.	55
Schering-Plough	6
Weill Medical College of Cornell University	2

Sponsor Type

Sponsor Type for REBETOL
Sponsor	Trials
Industry	84
Other	54
NIH	2

REBETOL (ribavirin) Clinical Trials Update, Market Analysis, and Projection

Last updated: April 27, 2026

What is REBETOL and what is its current clinical status?

REBETOL is the brand name for ribavirin, a nucleoside analog antiviral. In markets where REBETOL is marketed as a branded product, it is used primarily in combination regimens for chronic hepatitis C (HCV) and, historically, in combination therapies for other viral indications. Over the past decade, clinical and market focus has shifted toward direct-acting antivirals (DAAs), which displaced ribavirin from many standard-of-care pathways, except where ribavirin is used to manage treatment-specific constraints (for example, regimen selection, patient factors, or specific clinical scenarios in older or non-DAA pathways).

What do recent ribavirin clinical trial updates show?

Recent clinical trial activity for ribavirin is less about establishing new ribavirin monotherapies and more about:

• Combination optimization (ribavirin paired with older backbone regimens or with newer agents in defined settings)
• Special populations and treatment duration or intolerance strategies in historic HCV care pathways
• Resistance and relapse characterization in older direct-combination contexts
• Real-world effectiveness and toxicity profiling, especially anemia risk and discontinuation patterns

Regulatory/portfolio reality: ribavirin is an older molecule with long clinical history. The practical “update” for REBETOL is less “new efficacy breakthrough” and more “where it still appears in regimen structures” in the presence of DAAs. That shift drives the market outlook more than any new phase 3 program.

What does the evidence base show for ribavirin in HCV?

Across clinical literature, ribavirin has had two consistent roles:

1. Dose-dependent antiviral effect in interferon-based HCV regimens (historical backbone therapy)
2. Combination partner function that improves sustained virologic response (SVR) in older regimens, at the cost of clinically relevant adverse events (notably anemia)

In the DAA-dominant era, ribavirin usage has contracted sharply. Where it persists, it is typically in regimens or patient contexts that reflect older standards of care, resource environments, or prescriber decisions tied to tolerability and virologic risk.

---

How big is the ribavirin/REBETOL market today?

The ribavirin market is driven by:

• Persisting demand in HCV treatment settings where DAAs are not fully adopted or are constrained by payer coverage
• Stock and channel inventory cycles for older regimens
• Generic ribavirin competition that compresses branded pricing

Because ribavirin is widely available as a generic, branded REBETOL share and pricing power are structurally limited in most geographies. The market is therefore best modeled as a declining-to-flat “legacy HCV” demand pool with pricing pressure.

Market demand mechanics (what moves units)

REBETOL unit demand correlates with:

• Total HCV treatment volumes in a geography
• The proportion of those volumes that use non-DAA or ribavirin-containing protocols
• Access and reimbursement dynamics for DAAs
• Migration to modern pangenotypic DAA regimens that reduce or eliminate ribavirin use

Commercial headwind: generic substitution

Ribavirin is off-patent. Branded REBETOL competes against generic ribavirin on price and formulary preference. That factor dominates near-term revenue trajectory even if HCV therapy volumes stabilize.

---

What is the competitive landscape versus branded REBETOL?

Key competitive categories:

• Generic ribavirin (bulk of realized volume share in most markets)
• DAAs that reduce ribavirin reliance (direct substitutes in regimen design)
• Potential off-label or alternative viral use cases that, where not standardized, do not reliably support volume

Net effect: branded REBETOL typically behaves like a legacy product with limited incremental uptake.

---

What is the regulatory and patent landscape impact on REBETOL?

Ribavirin is an established older molecule. For investment and R&D planning, the main consequence is:

• Branded REBETOL is exposed to generic pricing pressure
• Any growth is constrained by standard-of-care evolution toward ribavirin-sparing DAA regimens

This makes REBETOL less an engine for expansion and more a predictable legacy cash-flow line, subject to local formulary and access patterns.

---

What is the clinical and commercial projection for REBETOL over the next 5 years?

REBETOL’s forecast should be modeled as a function of three variables:

1. HCV patient treatment volume (steady to declining with global HCV elimination programs)
2. Ribavirin regimen share within that volume (declining as DAAs penetrate)
3. Branded pricing discount versus generics (persistently negative)

Base-case projection logic

• Units: gradual decline as ribavirin-containing protocols narrow
• Revenue: more resilient than units only if branded pricing holds locally, but generics tend to keep branded price-to-generic spreads tight
• Volatility: limited, because demand is legacy-anchored rather than driven by new indications

Scenario projection (directional)

Scenario	Regimen share using ribavirin	Unit trend	Revenue trend for branded REBETOL
Base case	Continues to decline	Gradual decline	Declines slower than units (pricing mix)
Upside	Stabilizes in constrained-access settings	Flat to slight decline	Stabilizes then modest erosion
Downside	Accelerated DAA adoption	Faster decline	Sharper revenue contraction

---

What are the key clinical drivers that continue to affect use?

Even in a DAA era, ribavirin use can persist due to:

• Anemia management tradeoffs and regimen-specific patient tolerance
• Regimen sequencing and treatment class selection in older or resource-limited settings
• Clinical decision-making in complex cases where a clinician historically used ribavirin as part of the therapeutic balance

These drivers do not create growth comparable to DAAs, but they do set the floor for legacy demand.

---

Are there current-significance REBETOL clinical trials with near-term market implications?

REBETOL’s near-term market implication depends on whether ribavirin regains a standard-of-care position through new trials that change practice. The prevailing clinical development posture for ribavirin is not consistent with a broad practice shift in HCV compared with DAAs.

For business planning, treat REBETOL as:

• Practice-anchored legacy usage
• Generic-substitutable commodity risk
• No clear basis for major uptake acceleration without a new regimen standard

---

Key operational implications for decision-makers

If you are planning R&D

• Investing in “new ribavirin indications” is commercially high-risk given the long-established molecule, generic pressure, and the DAA-driven HCV standard evolution.
• The highest defensible pathway typically involves niche combinations or differentiated formulations where you can create payer and clinician-specific adoption.

If you are planning commercial strategy

• Branded REBETOL should be evaluated as a portfolio defense product, not a growth engine.
• Focus on geographies and contracts where branded positioning survives against generics through formulary status, supply continuity, and payer behavior.

If you are planning investment

• Model revenue as a decaying annuity with localized variability tied to DAA adoption and reimbursement.
• Discount rates should reflect competitive substitution from generic ribavirin and regimen substitution from DAAs.

---

Key Takeaways

• REBETOL (ribavirin) is a legacy HCV antiviral whose current market role is dominated by declining ribavirin regimen share as DAAs expand.
• Clinical “updates” are largely practice evolution rather than new breakthrough evidence that changes standard-of-care.
• Market outlook is a decline-with-floor profile driven by remaining ribavirin-containing protocols, local access constraints, and persistent generic substitution.
• Forecasts should emphasize scenario modeling by regimen share, not by clinical efficacy narratives.

---

FAQs

1) Is REBETOL used in modern HCV regimens?
It can remain in specific legacy or constrained-access protocols, but DAAs have reduced ribavirin reliance across most modern pathways.

2) What is the main commercial threat to branded REBETOL?
Generic ribavirin substitution and DAA regimen replacement.

3) What adverse effect most affects ribavirin use in practice?
Ribavirin is associated with anemia, which drives dose adjustments and discontinuations in some patients.

4) Can new clinical trials materially change REBETOL demand?
Only if new trials establish ribavirin’s role in a new regimen standard that expands prescribing beyond legacy contexts.

5) How should REBETOL be modeled for revenue planning?
As a legacy cash-flow line tied to the residual share of ribavirin-containing HCV protocols in each geography, with pricing erosion risk from generics.

---

References

[1] European Medicines Agency. Rebetol (ribavirin) product information. EMA.
[2] U.S. Food and Drug Administration. Rebetol (ribavirin) prescribing information. FDA.
[3] World Health Organization. Hepatitis C fact sheets and treatment guidance resources. WHO.
[4] Centers for Disease Control and Prevention. Hepatitis C clinical care guidance resources. CDC.
[5] Literature on ribavirin’s role in interferon-based and combination HCV regimens (SVR outcomes and anemia risk).